Inhibrx Biosciences reports positive Phase 2 results for head and neck cancer therapy
Inhibrx Biosciences said its INBRX-106 in combination with pembrolizumab produced positive results in a Phase 2 study for metastatic or unresectable recurrent head and neck squamous cell carcinoma.